<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450994</url>
  </required_header>
  <id_info>
    <org_study_id>EK15-2015_V1</org_study_id>
    <nct_id>NCT02450994</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude</brief_title>
  <official_title>Dexamethasone for Prophylaxis of Sleep Related Breathing Disturbances in Patients With Chronic Obstructive Pulmonary Disease (COPD) Travelling to Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Cardiology and Internal Medicine, Kyrgyzstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo controlled trial evaluating efficacy of dexamethasone in preventing sleep
      related breathing disturbances in lowlanders with chronic obstructive lung disease travelling
      from 700 m to 3200 m.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind parallel trial evaluating the efficacy
      of dexamethasone prophylaxis in sleep related breathing disturbances in lowlanders with
      chronic obstructive pulmonary disease travelling to altitude. Participants living in the
      Bishkek area, Kyrgyzstan (700m), will be transferred by car within 4h to the Tuja Ashu high
      altitude clinic (3200 m), and stay there for 2 days. Dexamethasone 2x4mg/day (or placebo),
      will be administered before departure at 700 m and during the stay at altitude. Outcomes will
      be assessed during the stay at 3200 m
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean nocturnal oxygen saturation measured by pulse oximetry</measure>
    <time_frame>night 1 at 3200 m</time_frame>
    <description>Difference in mean nocturnal oxygen saturation between dexamethasone and placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation index</measure>
    <time_frame>night 1 at 3200 m</time_frame>
    <description>Difference in oxygen desaturation index (&gt;3%) between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean nocturnal oxygen saturation measured by pulse oximetry</measure>
    <time_frame>night 2 at 3200 m</time_frame>
    <description>Difference in mean nocturnal oxygen saturation between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea/hypopnea index</measure>
    <time_frame>night 2 at 3200 m</time_frame>
    <description>Difference in mean apneas/hypopneas per hour between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea/hypopnea index</measure>
    <time_frame>night 1 at 3200 m</time_frame>
    <description>Difference in mean apneas/hypopneas per hour between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation index</measure>
    <time_frame>night 2 at 3200 m</time_frame>
    <description>Difference in oxygen desaturation index (&gt;3%) between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean nocturnal oxygen saturation measured by pulse oximetry</measure>
    <time_frame>night 1 at 700 m</time_frame>
    <description>Difference in mean nocturnal oxygen saturation between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation index</measure>
    <time_frame>night 1 at 700 m</time_frame>
    <description>Difference in oxygen desaturation index (&gt;3%) between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea/hypopnea index</measure>
    <time_frame>night 1 at 700 m</time_frame>
    <description>Difference in mean apneas/hypopneas per hour between the dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor vigilance test reaction time</measure>
    <time_frame>day 2 at 700 m</time_frame>
    <description>Difference in reaction time during psychomotor vigilance test between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sleepiness</measure>
    <time_frame>day 2 at 700 m</time_frame>
    <description>Difference in subjective sleepiness and sleep quality assessed by a visual analog scale between dexamethasone and placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sleepiness</measure>
    <time_frame>day 2 at 3200 m</time_frame>
    <description>Difference in subjective sleepiness and sleep quality assessed by a visual analog scale between dexamethasone and placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 4 mg capsules, twice per day, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules twice per day, orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic obstructive pulmonary disease (COPD), GOLD grade 1-2

          -  Living at low altitude (&lt;800m)

        Exclusion Criteria:

          -  COPD exacerbation

          -  severe COPD, GOLD grade 3 or 4

          -  arterial oxygen saturation &lt;92% at low altitude (&lt;800 m)

          -  Diabetes, uncontrolled cardiovascular disease such as systemic arterial hypertension,
             coronary artery disease; previous stroke; pneumothorax in the last 2 months, untreated
             or symptomatic peptic ulcer disease, glaucoma, obstructive sleep apnea.

          -  Internal, neurologic or psychiatric disease that interfere with protocol compliance
             including current heavy smoking (&gt;20 cigarettes per day).

          -  pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, ZÃ¼rich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talant M Sooronbaev, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center of Cardiology and Internal Medicine</name>
      <address>
        <city>Bishkek</city>
        <zip>720040</zip>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kyrgyzstan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>December 18, 2015</last_update_submitted>
  <last_update_submitted_qc>December 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>airway disease</keyword>
  <keyword>bronchitis</keyword>
  <keyword>emphysema</keyword>
  <keyword>lung</keyword>
  <keyword>treatment</keyword>
  <keyword>sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

